BiotechTube

Telithromycin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Maxillary Sinusitis

Conditions

Maxillary Sinusitis

Trial Timeline

Dec 1, 2002 → Sep 1, 2003

NCT ID
NCT00537563

About Telithromycin

Telithromycin is a phase 3 stage product being developed by Sanofi for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00537563. Target conditions include Maxillary Sinusitis.

What happened to similar drugs?

2 of 4 similar drugs in Maxillary Sinusitis were approved

Approved (2) Terminated (1) Active (2)
✅Azithromycin + TelithromycinSanofiApproved
✅Avelox (Moxifloxacin, BAY12-8039)BayerApproved
🔄levofloxacinJohnson & JohnsonPhase 3
🔄azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacinPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00288223ApprovedTerminated
NCT00261105ApprovedCompleted
NCT00174694ApprovedCompleted
NCT00546676ApprovedCompleted
NCT00132938ApprovedCompleted
NCT00538018ApprovedCompleted
NCT00273520Phase 3Completed
NCT00537563Phase 3Completed
NCT00538148ApprovedCompleted

Competing Products

5 competing products in Maxillary Sinusitis

See all competitors
ProductCompanyStageHype Score
levofloxacinJohnson & JohnsonPhase 3
40
Azithromycin SR + Amoxiclav 1000 mgPfizerPre-clinical
26
azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacinPfizerPhase 3
40
Azithromycin + TelithromycinSanofiApproved
35
Avelox (Moxifloxacin, BAY12-8039)BayerApproved
40